請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/8897
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 江伯倫 | |
dc.contributor.author | Yu-Ju Cheng | en |
dc.contributor.author | 程玉如 | zh_TW |
dc.date.accessioned | 2021-05-20T20:03:37Z | - |
dc.date.available | 2014-09-15 | |
dc.date.available | 2021-05-20T20:03:37Z | - |
dc.date.copyright | 2009-09-15 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-08-18 | |
dc.identifier.citation | Apostolou, I., and von Boehmer, H. (2004). In vivo instruction of suppressor commitment in naive T cells. J Exp Med 199, 1401-1408.
Aricha, R., Feferman, T., Souroujon, M.C., and Fuchs, S. (2006). Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. FASEB J 20, 374-376. Bacchetta, R., Bigler, M., Touraine, J.L., Parkman, R., Tovo, P.A., Abrams, J., de Waal Malefyt, R., de Vries, J.E., and Roncarolo, M.G. (1994). High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 179, 493-502. Bacchetta, R., Sartirana, C., Levings, M.K., Bordignon, C., Narula, S., and Roncarolo, M.G. (2002). Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur J Immunol 32, 2237-2245. Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.J., Pulendran, B., and Palucka, K. (2000). Immunobiology of dendritic cells. Annu Rev Immunol 18, 767-811. Banchereau, J., and Steinman, R.M. (1998). Dendritic cells and the control of immunity. Nature 392, 245-252. Battaglia, M., Gianfrani, C., Gregori, S., and Roncarolo, M.G. (2004). IL-10-producing T regulatory type 1 cells and oral tolerance. Ann N Y Acad Sci 1029, 142-153. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T.B., Oukka, M., Weiner, H.L., and Kuchroo, V.K. (2006). Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238. Brinker, A.M., Ma, J., Lipsky, P.E., and Raskin, I. (2007). Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 68, 732-766. Brooks, D.G., Trifilo, M.J., Edelmann, K.H., Teyton, L., McGavern, D.B., and Oldstone, M.B. (2006). Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 12, 1301-1309. Cantrell, D.A., and Smith, K.A. (1984). The interleukin-2 T-cell system: a new cell growth model. Science 224, 1312-1316. Cavani, A., Nasorri, F., Prezzi, C., Sebastiani, S., Albanesi, C., and Girolomoni, G. (2000). Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol 114, 295-302. Chan, A.C., Dalton, M., Johnson, R., Kong, G.H., Wang, T., Thoma, R., and Kurosaki, T. (1995). Activation of ZAP-70 kinase activity by phosphorylation of tyrosine 493 is required for lymphocyte antigen receptor function. EMBO J 14, 2499-2508. Chan, M.A., Kohlmeier, J.E., Branden, M., Jung, M., and Benedict, S.H. (1999). Triptolide is more effective in preventing T cell proliferation and interferon-gamma production than is FK506. Phytother Res 13, 464-467. Chen, W., Jin, W., Hardegen, N., Lei, K.J., Li, L., Marinos, N., McGrady, G., and Wahl, S.M. (2003). Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198, 1875-1886. Chen, X., Murakami, T., Oppenheim, J.J., and Howard, O.M. (2005). Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking. Blood 106, 2409-2416. Chen, Y., Kuchroo, V.K., Inobe, J., Hafler, D.A., and Weiner, H.L. (1994). Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265, 1237-1240. Colonna, M., Pulendran, B., and Iwasaki, A. (2006). Dendritic cells at the host-pathogen interface. Nat Immunol 7, 117-120. Colonna, M., Trinchieri, G., and Liu, Y.J. (2004). Plasmacytoid dendritic cells in immunity. Nat Immunol 5, 1219-1226. Danielian, S., Alcover, A., Polissard, L., Stefanescu, M., Acuto, O., Fischer, S., and Fagard, R. (1992). Both T cell receptor (TcR)-CD3 complex and CD2 increase the tyrosine kinase activity of p56lck. CD2 can mediate TcR-CD3-independent and CD45-dependent activation of p56lck. Eur J Immunol 22, 2915-2921. Depper, J.M., Leonard, W.J., Drogula, C., Kronke, M., Waldmann, T.A., and Greene, W.C. (1985). Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. Proc Natl Acad Sci U S A 82, 4230-4234. Dhodapkar, M.V., Steinman, R.M., Krasovsky, J., Munz, C., and Bhardwaj, N. (2001). Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193, 233-238. Dustin, M.L., and Springer, T.A. (1989). T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 341, 619-624. Fallarino, F., Grohmann, U., Vacca, C., Bianchi, R., Orabona, C., Spreca, A., Fioretti, M.C., and Puccetti, P. (2002). T cell apoptosis by tryptophan catabolism. Cell Death Differ 9, 1069-1077. Fantini, M.C., Becker, C., Monteleone, G., Pallone, F., Galle, P.R., and Neurath, M.F. (2004). Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172, 5149-5153. Fantini, M.C., Becker, C., Tubbe, I., Nikolaev, A., Lehr, H.A., Galle, P., and Neurath, M.F. (2006). Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut 55, 671-680. Finkelman, F.D., Urban, J.F., Jr., Beckmann, M.P., Schooley, K.A., Holmes, J.M., and Katona, I.M. (1991). Regulation of murine in vivo IgG and IgE responses by a monoclonal anti-IL-4 receptor antibody. Int Immunol 3, 599-607. Gallucci, S., and Matzinger, P. (2001). Danger signals: SOS to the immune system. Curr Opin Immunol 13, 114-119. Gauchat, J.F., Aversa, G., Gascan, H., and de Vries, J.E. (1992). Modulation of IL-4 induced germline epsilon RNA synthesis in human B cells by tumor necrosis factor-alpha, anti-CD40 monoclonal antibodies or transforming growth factor-beta correlates with levels of IgE production. Int Immunol 4, 397-406. Gimmi, C.D., Freeman, G.J., Gribben, J.G., Gray, G., and Nadler, L.M. (1993). Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A 90, 6586-6590. Gonzalez-Amaro, R., Portales-Perez, D., Baranda, L., Redondo, J.M., Martinez-Martinez, S., Yanez-Mo, M., Garcia-Vicuna, R., Cabanas, C., and Sanchez-Madrid, F. (1998). Pentoxifylline inhibits adhesion and activation of human T lymphocytes. J Immunol 161, 65-72. Gould, H.J., Sutton, B.J., Beavil, A.J., Beavil, R.L., McCloskey, N., Coker, H.A., Fear, D., and Smurthwaite, L. (2003). The biology of IGE and the basis of allergic disease. Annu Rev Immunol 21, 579-628. Groux, H., O'Garra, A., Bigler, M., Rouleau, M., Antonenko, S., de Vries, J.E., and Roncarolo, M.G. (1997). A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737-742. Gu, W.Z., Chen, R., Brandwein, S., McAlpine, J., and Burres, N. (1995). Isolation, purification, and characterization of immunosuppressive compounds from tripterygium: triptolide and tripdiolide. Int J Immunopharmacol 17, 351-356. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J.V., Steinman, R.M., and Nussenzweig, M.C. (2001). Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194, 769-779. Huter, E.N., Punkosdy, G.A., Glass, D.D., Cheng, L.I., Ward, J.M., and Shevach, E.M. (2008). TGF-beta-induced Foxp3+ regulatory T cells rescue scurfy mice. Eur J Immunol 38, 1814-1821. Iwasaki, A., and Medzhitov, R. (2004). Toll-like receptor control of the adaptive immune responses. Nat Immunol 5, 987-995. Jacobson, N.G., Szabo, S.J., Guler, M.L., Gorham, J.D., and Murphy, K.M. (1996). Regulation of interleukin-12 signalling during T helper phenotype development. Adv Exp Med Biol 409, 61-73. Jiang, X. (1994). Clinical observations on the use of the Chinese herb Tripterygium wilfordii Hook for the treatment of nephrotic syndrome. Pediatr Nephrol 8, 343-344. Jonuleit, H., Schmitt, E., Schuler, G., Knop, J., and Enk, A.H. (2000). Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192, 1213-1222. Kato, M., Neil, T.K., Fearnley, D.B., McLellan, A.D., Vuckovic, S., and Hart, D.N. (2000). Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells. Int Immunol 12, 1511-1519. Kupchan, S.M., Court, W.A., Dailey, R.G., Jr., Gilmore, C.J., and Bryan, R.F. (1972). Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc 94, 7194-7195. Law, W.R., Nadkarni, V.M., Fletcher, M.A., Nevola, J.J., Eckstein, J.M., Quance, J., McKenna, T.M., Lee, C.H., and Williams, T.J. (1992). Pentoxifylline treatment of sepsis in conscious Yucatan minipigs. Circ Shock 37, 291-300. Lee, K.Y., Chang, W., Qiu, D., Kao, P.N., and Rosen, G.D. (1999). PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem 274, 13451-13455. Li, L.F. (2000). Treatment of pyoderma gangrenosum with oral Tripterygium wilfordii multiglycoside. J Dermatol 27, 478-481. Lighvani, A.A., Frucht, D.M., Jankovic, D., Yamane, H., Aliberti, J., Hissong, B.D., Nguyen, B.V., Gadina, M., Sher, A., Paul, W.E., et al. (2001). T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci U S A 98, 15137-15142. Lipsky, P.E., and Tao, X.L. (1997). A potential new treatment for rheumatoid arthritis: thunder god vine. Semin Arthritis Rheum 26, 713-723. Liu, H., Liu, Z.H., Chen, Z.H., Yang, J.W., and Li, L.S. (2000). Triptolide: a potent inhibitor of NF-kappa B in T-lymphocytes. Acta Pharmacol Sin 21, 782-786. Liu, Q., Chen, T., Chen, G., Shu, X., Sun, A., Ma, P., Lu, L., and Cao, X. (2007a). Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 expression through PI3-K/Akt and NF-kappaB pathways. Mol Immunol 44, 2686-2696. Liu, Q., Chen, T., Chen, H., Zhang, M., Li, N., Lu, Z., Ma, P., and Cao, X. (2004). Triptolide (PG-490) induces apoptosis of dendritic cells through sequential p38 MAP kinase phosphorylation and caspase 3 activation. Biochem Biophys Res Commun 319, 980-986. Liu, Y., Chen, Y., Lamb, J.R., and Tam, P.K. (2007b). Triptolide, a component of Chinese herbal medicine, modulates the functional phenotype of dendritic cells. Transplantation 84, 1517-1526. Liu, Y.J., Kanzler, H., Soumelis, V., and Gilliet, M. (2001). Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2, 585-589. Lu, H., Hachida, M., Enosawa, S., Li, X.K., Suzuki, S., and Koyanagi, H. (1999). Immunosuppressive effect of triptolide in vitro. Transplant Proc 31, 2056-2057. Lu, L., McCaslin, D., Starzl, T.E., and Thomson, A.W. (1995). Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation 60, 1539-1545. Lucas, P.J., Kim, S.J., Melby, S.J., and Gress, R.E. (2000). Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J Exp Med 191, 1187-1196. Lundqvist, A., Palmborg, A., Pavlenko, M., Levitskaya, J., and Pisa, P. (2005). Mature dendritic cells induce tumor-specific type 1 regulatory T cells. J Immunother 28, 229-235. Macatonia, S.E., Hosken, N.A., Litton, M., Vieira, P., Hsieh, C.S., Culpepper, J.A., Wysocka, M., Trinchieri, G., Murphy, K.M., and O'Garra, A. (1995). Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 154, 5071-5079. Mahnke, K., Qian, Y., Knop, J., and Enk, A.H. (2003). Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 101, 4862-4869. Mahnke, K., Schmitt, E., Bonifaz, L., Enk, A.H., and Jonuleit, H. (2002). Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol 80, 477-483. Mahon, B.P., Katrak, K., Nomoto, A., Macadam, A.J., Minor, P.D., and Mills, K.H. (1995). Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor. J Exp Med 181, 1285-1292. Maksymowych, W.P., Avina-Zubieta, A., Luong, M.H., and Russell, A.S. (1995). An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol 22, 625-629. Mandi, Y., Farkas, G., Ocsovszky, I., and Nagy, Z. (1995). Inhibition of tumor necrosis factor production and ICAM-1 expression by pentoxifylline: beneficial effects in sepsis syndrome. Res Exp Med (Berl) 195, 297-307. Mellor, A.L., and Munn, D.H. (2004). IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4, 762-774. Moher, D., Pham, B., Ausejo, M., Saenz, A., Hood, S., and Barber, G.G. (2000). Pharmacological management of intermittent claudication: a meta-analysis of randomised trials. Drugs 59, 1057-1070. Moller, D.R., Wysocka, M., Greenlee, B.M., Ma, X., Wahl, L., Trinchieri, G., and Karp, C.L. (1997). Inhibition of human interleukin-12 production by pentoxifylline. Immunology 91, 197-203. Munn, D.H., Sharma, M.D., Lee, J.R., Jhaver, K.G., Johnson, T.S., Keskin, D.B., Marshall, B., Chandler, P., Antonia, S.J., Burgess, R., et al. (2002). Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297, 1867-1870. Nathan, C.F., Murray, H.W., Wiebe, M.E., and Rubin, B.Y. (1983). Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 158, 670-689. Novak, N., and Bieber, T. (2008). 2. Dendritic cells as regulators of immunity and tolerance. J Allergy Clin Immunol 121, S370-374; quiz S413. O'Byrne, P.M., Inman, M.D., and Parameswaran, K. (2001). The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol 108, 503-508. Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D.P., and Gabrilovich, D.I. (1998). Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 160, 1224-1232. Penna, G., and Adorini, L. (2000). 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164, 2405-2411. Piemonti, L., Monti, P., Allavena, P., Sironi, M., Soldini, L., Leone, B.E., Socci, C., and Di Carlo, V. (1999). Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 162, 6473-6481. Piemonti, L., Monti, P., Sironi, M., Fraticelli, P., Leone, B.E., Dal Cin, E., Allavena, P., and Di Carlo, V. (2000). Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 164, 4443-4451. Prud'homme, G.J., and Piccirillo, C.A. (2000). The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases. J Autoimmun 14, 23-42. Qin, W.Z., Liu, C.H., and Yang, S.M. (1981). Tripterygium Wilfordii Hook F in systemic lupus erythematosus: report of 103 cases. Chin Med J (Engl) 94, 827-834. Qin, W.Z., Zhu, G.D., Yang, S.M., Han, K.Y., and Wang, J. (1983). Clinical observations on Tripterygium wilfordii in treatment of 26 cases of discoid lupus erythematosus. J Tradit Chin Med 3, 131-132. Qiu, D., and Kao, P.N. (2003). Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D 4, 1-18. Qiu, D., Zhao, G., Aoki, Y., Shi, L., Uyei, A., Nazarian, S., Ng, J.C., and Kao, P.N. (1999). Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 274, 13443-13450. Raveh, D., Kruskal, B.A., Farland, J., and Ezekowitz, R.A. (1998). Th1 and Th2 cytokines cooperate to stimulate mannose-receptor-mediated phagocytosis. J Leukoc Biol 64, 108-113. Reefer, A.J., Carneiro, R.M., Custis, N.J., Platts-Mills, T.A., Sung, S.S., Hammer, J., and Woodfolk, J.A. (2004). A role for IL-10-mediated HLA-DR7-restricted T cell-dependent events in development of the modified Th2 response to cat allergen. J Immunol 172, 2763-2772. Reid, S.D., Penna, G., and Adorini, L. (2000). The control of T cell responses by dendritic cell subsets. Curr Opin Immunol 12, 114-121. Reiser, H., Freeman, G.J., Razi-Wolf, Z., Gimmi, C.D., Benacerraf, B., and Nadler, L.M. (1992). Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sci U S A 89, 271-275. Rieckmann, P., Weber, F., Gunther, A., Martin, S., Bitsch, A., Broocks, A., Kitze, B., Weber, T., Borner, T., and Poser, S. (1996). Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 64, 193-200. Roncarolo, M.G., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K., and Levings, M.K. (2006). Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212, 28-50. Saloga, J., Bellinghausen, I., and Knop, J. (1999). Do Tr1 cells play a role in immunotherapy? Int Arch Allergy Immunol 118, 210-211. Samardzic, T., Jankovic, V., Stosic-Grujicic, S., Popadic, D., and Trajkovic, V. (2001). Pentoxifylline inhibits the synthesis and IFN-gamma-inducing activity of IL-18. Clin Exp Immunol 124, 274-281. Samlaska, C.P., and Winfield, E.A. (1994). Pentoxifylline. J Am Acad Dermatol 30, 603-621. Schoenberger, S.P., Toes, R.E., van der Voort, E.I., Offringa, R., and Melief, C.J. (1998). T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483. Schwarz, A., Krone, C., Trautinger, F., Aragane, Y., Neuner, P., Luger, T.A., and Schwarz, T. (1993). Pentoxifylline suppresses irritant and contact hypersensitivity reactions. J Invest Dermatol 101, 549-552. Shedlock, D.J., and Shen, H. (2003). Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337-339. Shull, M.M., Ormsby, I., Kier, A.B., Pawlowski, S., Diebold, R.J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992). Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359, 693-699. Steinbrink, K., Wolfl, M., Jonuleit, H., Knop, J., and Enk, A.H. (1997). Induction of tolerance by IL-10-treated dendritic cells. J Immunol 159, 4772-4780. Steinman, R.M., and Nussenzweig, M.C. (2002). Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 99, 351-358. Steinman, R.M., Turley, S., Mellman, I., and Inaba, K. (2000). The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191, 411-416. Suss, G., and Shortman, K. (1996). A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med 183, 1789-1796. Swain, S.L., Weinberg, A.D., English, M., and Huston, G. (1990). IL-4 directs the development of Th2-like helper effectors. J Immunol 145, 3796-3806. Tao, X., Cai, J.J., and Lipsky, P.E. (1995). The identity of immunosuppressive components of the ethyl acetate extract and chloroform methanol extract (T2) of Tripterygium wilfordii Hook. F. J Pharmacol Exp Ther 272, 1305-1312. Tao, X., Davis, L.S., and Lipsky, P.E. (1991). Effect of an extract of the Chinese herbal remedy Tripterygium wilfordii Hook F on human immune responsiveness. Arthritis Rheum 34, 1274-1281. Tao, X., Schulze-Koops, H., Ma, L., Cai, J., Mao, Y., and Lipsky, P.E. (1998). Effects of Tripterygium wilfordii hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis Rheum 41, 130-138. Tao, X.L., Sun, Y., Dong, Y., Xiao, Y.L., Hu, D.W., Shi, Y.P., Zhu, Q.L., Dai, H., and Zhang, N.Z. (1989). A prospective, controlled, double-blind, cross-over study of tripterygium wilfodii hook F in treatment of rheumatoid arthritis. Chin Med J (Engl) 102, 327-332. Toribio, M.L., Gutierrez-Ramos, J.C., Pezzi, L., Marcos, M.A., and Martinez, C. (1989). Interleukin-2-dependent autocrine proliferation in T-cell development. Nature 342, 82-85. Vukanic, Z.S., Colic, M., and Dimitrijevic, M. (2007). Effect of pentoxifylline on differentiation and maturation of human monocyte-derived dendritic cells in vitro. Int Immunopharmacol 7, 167-174. Wakkach, A., Fournier, N., Brun, V., Breittmayer, J.P., Cottrez, F., and Groux, H. (2003). Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18, 605-617. Ward, A., and Clissold, S.P. (1987). Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34, 50-97. Weiner, H.L. (2001). Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 182, 207-214. Whitehouse, M.W. (2004). Anti-TNF-alpha therapy for chronic inflammation: reconsidering pentoxifylline as an alternative to therapeutic protein drugs. Inflammopharmacology 12, 223-227. Wilson, N.S., El-Sukkari, D., and Villadangos, J.A. (2004). Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. Blood 103, 2187-2195. Wu, C.C., Liao, M.H., Chen, S.J., and Yen, M.H. (1999). Pentoxifylline improves circulatory failure and survival in murine models of endotoxaemia. Eur J Pharmacol 373, 41-49. Yang, S.X., Xie, S.S., Gao, H.L., Ma, D.L., and Long, Z.Z. (1994). Triptolide suppresses T-lymphocyte proliferation by inhibiting interleukin-2 receptor expression, but spares interleukin-2 production and mRNA expression. Int J Immunopharmacol 16, 895-904. Yang, Y., Liu, Z., Tolosa, E., Yang, J., and Li, L. (1998). Triptolide induces apoptotic death of T lymphocyte. Immunopharmacology 40, 139-149. Yudoh, K., Matsuno, H., Nakazawa, F., Yonezawa, T., and Kimura, T. (2000). Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis Rheum 43, 617-627. Zhang, R., Bharadwaj, U., Li, M., Chen, C., and Yao, Q. (2007). Effects of pentoxifylline on differentiation, maturation, and function of human CD14+ monocyte-derived dendritic cells. J Immunother 30, 89-95. Zheng, S.G., Wang, J., Wang, P., Gray, J.D., and Horwitz, D.A. (2007). IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 178, 2018-2027. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/8897 | - |
dc.description.abstract | 現今有許多的疾病都被證實是由體內產生過度的免疫反應所造成,例如移植體對宿主反應(GVHD)、氣喘(asthma),或是自體免疫方面的疾病,例如:類風濕性關節炎(RA)、多發性硬化症(MS)、及紅斑性狼瘡(SLE)等等。目前市面上很多免疫抑制藥物可供治療使用,卻也伴隨著副作用的產生。配妥西菲林(pentoxifylline)和雷公藤內酯醇(triptolide)這兩種藥物在臨床上已經被使用在治療許多不同的疾病上,也顯示出具有某種程度上能調節免疫的功能,但是當中詳細的機制還沒有完全了解清楚。因此在我們的實驗當中,我們利用T細胞接受器基因轉殖小鼠的CD4 T細胞以及BALB/c小鼠的樹突細胞來研究配妥西菲林(pentoxifylline)和雷公藤內酯醇(triptolide)的免疫調節功能。實驗中我們針對藥物影響細胞分泌細胞激素的量、細胞表面上標誌分子的表現、以及細胞增生的情形來觀察。實驗結果發現,配妥西菲林(pentoxifylline)和雷公藤內酯醇(triptolide)兩種藥物都能有效的抑制CD4 T細胞活化,不管是在介白素2的分泌上或者是細胞增生情況都有顯著被抑制的情形。同時實驗也發現這兩種藥物並不會去誘發T細胞表現類似調節性T細胞的特性,例如產生Foxp3分子表現或者是增加分泌介白素10的分泌量。而在藥物處理樹突細胞的實驗結果,發現配妥西菲林(pentoxifylline)會促進樹突細胞表現CD86分子,並且會促進樹突細胞分泌介白素12。而雷公藤內酯醇(triptolide)並不會對樹突細胞表面上分子的表現量有影響,但是可以有效的抑制樹突細胞分泌介白素12。在本次實驗當中我們可以了解到,配妥西菲林(pentoxifylline)以及雷公藤內酯醇(triptolide)可以藉由抑制CD4 T細胞活化來抑制免疫反應,但是卻不會透過誘導調節性T細胞產生。然而,配妥西菲林(pentoxifylline)和雷公藤內酯醇(triptolide)藉由不同機轉調節樹突細胞的功能,也能夠說明這兩種藥物可以各自用在各自不同的疾病治療上。 | zh_TW |
dc.description.abstract | Many diseases are well known to be caused by excessive and unexpected immune responses such as graft-versus-host diseases (GVHD), asthma, and other severe autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE). Up to the present time, many immunosuppressive drugs have been used to treat these diseases effectively to treat but with many side-effects. Pentoxifylline (PTX) and triptolide (TPT) are used in different kinds of diseases for a long time and show some immune regulatory functions, but the mechanisms are still not completely understood. In this study, we isolated CD4 T cells from DO11.10 mice and DCs from BALB/c mice. We treated these immune cells with PTX or TPT and analyzed their phenotype and function including cytokine secretion, cell surface markers expression, and cell proliferation. We found that both PTX and TPT inhibited CD4 T cells activation including IL-2 secretion and cell proliferation; however, they did not induce Foxp3 expression and IL-10 secretion, which are the important characteristics of regulatory T cells. On the other hand, we found that PTX induced the expression of CD86 on DCs and promoted IL-12 secretion, while TPT did not affect the surface marker expression on DCs and inhibited the IL-12 secretion. In the present study, we suggest that both PTX and TPT inhibit CD4 T cell activation, and their immunosuppressive functions might not mediate through regulatory T cell induction. In addition, these two drugs have different effects on dendritic cell functions, and these results show that they have the potential to be applied in different diseases. | en |
dc.description.provenance | Made available in DSpace on 2021-05-20T20:03:37Z (GMT). No. of bitstreams: 1 ntu-98-R96450013-1.pdf: 2050224 bytes, checksum: e2d81cce9bc165f060b0c4d0c82307f1 (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 摘要 ------------------------------------------------------------------------------------------------ I
Abstract --------------------------------------------------------------------------------------------II Contents ------------------------------------------------------------------------------------------IV Chapter I Introduction --------------------------------------------------------------------------1 Pentoxifylline ------------------------------------------------------------------------------------2 Triptolide -----------------------------------------------------------------------------------------3 Dendritic cells -----------------------------------------------------------------------------------6 CD4 T cells -------------------------------------------------------------------------------------13 Regulatory T cells -----------------------------------------------------------------------------16 Study Aims -------------------------------------------------------------------------------------20 Chapter II Materials & Methods ------------------------------------------------------------21 Materials Animals---------------------------------------------------------------------------------------22 Cell line---------------------------------------------------------------------------------------22 Cell culture reagents------------------------------------------------------------------------22 Drugs------------------------------------------------------------------------------------------24 ELISA assay ---------------------------------------------------------------------------------24 Flow cytometry------------------------------------------------------------------------------25 Magnetic cell sorting-----------------------------------------------------------------------26 Methods Isolation of naïve CD4 T cells-------------------------------------------------------------26 Cell toxicity test-----------------------------------------------------------------------------27 Culture of bone narrow-derived dendritic cells-----------------------------------------27 Drug treatment on CD4 T cells------------------------------------------------------------28 Drug treatment on bone marrow-derived dendritic cells-------------------------------29 Proliferation assay--------------------------------------------------------------------------30 Measurement of cytokine production----------------------------------------------------30 Flow cytometry analysis-------------------------------------------------------------------31 Chapter III Results -----------------------------------------------------------------------------33 Pentoxifylline The cell toxicity test of PTX---------------------------------------------------------------34 PTX can inhibit CD4 T cell proliferation and IL-2 secretion upon stimulation----34 PTX do not have the regulatory T cell induction function-----------------------------35 PTX can not affect the marker expression on BMDCs but selectively increase cytokine secretion---------------------------------------------------------------------------36 Inhibition of NF-κB prevent the IL-12p40 secretion changes induced by PTX----37 Triptolide The cell toxicity test of TPT---------------------------------------------------------------38 TPT can inhibit CD4 T cell proliferation and IL-2 secretion upon stimulation-----38 TPT do not induce regulatory T cell generation----------------------------------------39 TPT do not affect the surface marker expression on BMDCs but selectively increase cytokine secretion----------------------------------------------------------------39 Inhibition of ERK and p38 pathways prevent the IL-12p40 secretion affected by TPT--------------------------------------------------------------------------------------------40 Chapter IV Discussions & Conclusion------------------------------------------------------42 Pentoxifylline--------------------------------------------------------------------------------43 Triptolide-------------------------------------------------------------------------------------46 Conclusion-----------------------------------------------------------------------------------48 Figures ---------------------------------------------------------------------------------------------49 References ----------------------------------------------------------------------------------------68 | |
dc.language.iso | en | |
dc.title | 配妥西菲林以及雷公藤內酯醇對免疫細胞調控的機轉研究 | zh_TW |
dc.title | Study on the Effects of Pentoxifylline and Triptolide
on Immune Effector Cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 97-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 莊雅惠,周涵怡 | |
dc.subject.keyword | 配妥西菲林,雷公藤內酯醇,輔助行T細胞,樹突細胞, | zh_TW |
dc.subject.keyword | pentoxifylline,triptolide,CD4 T cell,dendritic cell, | en |
dc.relation.page | 79 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2009-08-18 | |
dc.contributor.author-college | 牙醫專業學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf | 2 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。